KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $68.5 million.

  • Aquestive Therapeutics' Net Cash Flow rose 672.15% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year decrease of 3.41%. This contributed to the annual value of $47.7 million for FY2024, which is 1501.76% up from last year.
  • Aquestive Therapeutics' Net Cash Flow amounted to $68.5 million in Q3 2025, which was up 943.82% from -$8.1 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Net Cash Flow registered a high of $71.3 million during Q1 2024, and its lowest value of -$13.3 million during Q1 2022.
  • In the last 3 years, Aquestive Therapeutics' Net Cash Flow had a median value of -$2.9 million in 2025 and averaged $9.3 million.
  • The largest annual percentage gain for Aquestive Therapeutics' Net Cash Flow in the last 5 years was 18,342.46% (2024), contrasted with its biggest fall of 582.75% (2024).
  • Aquestive Therapeutics' Net Cash Flow (Quarterly) stood at -$3.1 million in 2021, then soared by 374.65% to $8.6 million in 2022, then slumped by 112.12% to -$1.0 million in 2023, then crashed by 507.37% to -$6.3 million in 2024, then surged by 672.15% to $68.5 million in 2025.
  • Its last three reported values are $68.5 million in Q3 2025, -$8.1 million for Q2 2025, and -$2.9 million during Q1 2025.